ClinicalTrials.Veeva

Menu

Immunomodulation With Romiplostim in Young Adults With ITP (iROM)

University Hospital Basel logo

University Hospital Basel

Status and phase

Completed
Phase 4

Conditions

Immune Thrombocytopenia

Treatments

Drug: romiplostim

Study type

Interventional

Funder types

Other

Identifiers

NCT02760251
20149180

Details and patient eligibility

About

The study aims to investigate immunomodulatory effects of thrombopoietin-receptor Agonist (TPO-RA) in patients with primary ITP, who failed first-line therapy or who became intolerant to it. It is hypothesized that the early phase of this autoimmune disease may exhibit a stronger immunomodulatory potential in response to a stimulus, such as romiplostim. Such a process may subsequently be capable to induce regulatory mechanisms or tolerance.

Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC).

Enrollment

15 patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Informed consent as documented by signature (see informed consent form)
  • Primary ITP according to the definition of Rodeghiero et al. (52) and a platelet count of <30x109/l
  • Age range: 18-45 years
  • Previously treated patients, with failure or intolerance to first-line therapy, or relapse after first-line therapy, i.e. corticosteroids, intravenous immunoglobulin (IVIG), or anti-D immunoglobulins

Exclusion criteria

  • Adults older than 45 and children younger than 18 years
  • Platelet count higher than 30x109/l at time of screening
  • Suspicion of secondary ITP
  • Positive family history for ITP
  • Presence or history of autoimmune disease as judged by the investigator
  • Hepatosplenomegaly
  • Presence or history of relevant hepatic disease as judged by the investigator
  • Presence or history of thromboembolic disease as judged by the investigator
  • Patients with splenectomy
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Lack of safe double contraception (see 7.1)
  • Any vaccination 2 weeks prior start of the study
  • Drugs with a known impact on the immune system or on platelet function must be recorded and an exclusion of the study should be discussed with the study center
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the study subject
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Previous treatment with romiplostim or eltrombopag
  • Hypersensitivity to the active substance or to any of the excipients or to E. coli derived proteins
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

15 participants in 1 patient group

Romiplostim
Experimental group
Description:
Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC). Followup examination at week 52.
Treatment:
Drug: romiplostim

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems